ワクチン関連の各種提携契約：契約条件・合意内容

当レポートでは、ワクチン関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約タイプ・開発ステージ・疾患区分・技術区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 ワクチン関連の各種契約の動向

• イントロダクション
• 過去数年におけるワクチン関連の提携
• 大手製薬会社による契約活動
• ワクチン関連の事業に積極的でない大手製薬会社
• ワクチン関連の提携：契約タイプ別
• ワクチン関連の提携：疾患タイプ別
• 平均契約期間
• 前払い金
• 目標達成報酬
• ロイヤリティ料率

第3章 主要契約

• イントロダクション
• 主要契約：取引額別
• 大手製薬会社のかかわる主要契約

第4章 大手製薬会社による契約

• 提携企業のプロファイル

第5章 契約ディレクトリ

• イントロダクション
• 企業別：A-Z
• 開発ステージ別
  • 創薬
  • 前臨床
  • フェーズI
  • フェーズII
  • フェーズIII
  • 申請登録
  • 市販
• 契約タイプ別
  • 資産購入
  • 委託
  • 大手によるアウトライセンシング
  • 共同開発
  • 共同R&D
  • サービス契約
  • 共同プロモーション
  • CRADA
  • 開発
  • 流通販売
  • 株式購入
  • 評価
  • 援助
  • ジョイントベンチャー
  • ライセンシング
  • 訴訟関連
  • 製造
  • マーケティング
  • 材料転移
  • オプション
  • プロモーション
  • 研究
  • ロイヤルティファイナンシング
  • 和解関連
  • スピンアウト
  • サブライセンス
  • 供給
  • 技術移転
  • 停止
  • 保証
• 治療分野別
  • 麻酔
  • 心臓血管
  • 中枢神経
  • 歯科
  • 皮膚科
  • 消化管
  • 泌尿生殖器
  • 血液
  • 院内ケア
  • 免疫
  • 感染症
  • 炎症
  • 代謝異常
  • 筋骨格系
  • 癌
  • 眼科
  • 精神医学
  • 公衆衛生
  • 呼吸器
  • 性の健康
• 関連技術タイプ別
  • アジュバント

第6章 提携機会

• オンラインパートナリング
• パートナリングイベント
• 関連資料

付録

図表

The ‘Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials ’ report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in vaccine and adjuvant partnering deals
• Deal terms analysis
• Partnering agreement structure
• Partnering contract documents
• Top deals by value
• Most active dealmakers
• Average deal terms for vaccines

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2010, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 1,000 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field.

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it.

‘Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials ’ is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

‘Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials ’ includes:

• Trends in vaccine dealmaking in the biopharma industry since 2010
• Analysis of vaccine deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life vaccine deals
• Access to over 1,000 vaccine deal documents
• The leading vaccine deals by value since 2010
• Most active vaccine dealmakers since 2010
• The leading vaccine partnering resources

In ‘Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials ’, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Therapy target
• Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials ’ report provides comprehensive access to available deals and contract documents for over 880 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise vaccine rights granted or optioned?

• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What is the payment structure for the deal?

• How are sales and payments audited?

• What is the deal term?

• How are the key terms of the agreement defined?

• How are IPRs handled and owned?

• Who is responsible for commercialization?

• Who is responsible for development, supply, and manufacture?

• How is confidentiality and publication managed?

• How are disputes to be resolved?

• Under what conditions can the deal be terminated?

• What happens when there is a change of ownership?

• What sublicensing and subcontracting provisions have been agreed?

• Which boilerplate clauses does the company insist upon?

• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

• Which jurisdiction does the company insist upon for agreement law?

Benefits:

‘Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials ’ provides the reader with the following key benefits:

• In-depth understanding of vaccine and adjuvant deal trends since 2010

• Access to headline, upfront, milestone and royalty data

• Analysis of the structure of vaccine agreements with numerous real life case studies

• Comprehensive access to over 1,000 actual vaccine deals entered into by the world's biopharma companies, together with contract documents if available

• Detailed access to actual vaccine contracts enter into by leading bio pharma companies

• Identify leading vaccine deals by value since 2010

• Identify the most active vaccine dealmakers since 2010

• Insight into the terms included in a vaccine agreement, together with real world clause examples

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Vaccines dealmaking

• 2.1. Introduction
• 2.2. Vaccines partnering over the years
• 2.3. Most active Vaccines dealmakers
• 2.4. Vaccines partnering by deal type
• 2.5. Vaccines partnering by therapy area
• 2.6. Deal terms for Vaccines partnering
  • 2.6.1 Vaccines partnering headline values
  • 2.6.2 Vaccines deal upfront payments
  • 2.6.3 Vaccines deal milestone payments
  • 2.6.4 Vaccines royalty rates

Chapter 3 - Leading Vaccines deals

• 3.1. Introduction
• 3.2. Top Vaccines deals by value

Chapter 4 - Most active Vaccines dealmakers

• 4.1. Introduction
• 4.2. Most active Vaccines dealmakers
• 4.3. Most active Vaccines partnering company profiles

Chapter 5 - Vaccines contracts dealmaking directory

• 5.1. Introduction
• 5.2. Vaccines contracts dealmaking directory

Chapter 6 - Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center

• 7.1. Online partnering
• 7.2. Partnering events
• 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Vaccines deals by company A-Z

Appendix 2 - Vaccines deals by stage of development

• Discovery
• Preclinical
• Phase I
• Phase II
• Phase III
• Regulatory
• Marketed
• Formulation

Appendix 3 - Vaccines deals by deal type

• Asset purchase
• Assignment
• Bigpharma outlicensing
• Co-development
• Collaborative R&D
• Co-market
• Co-promotion
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Manufacturing
• Marketing
• Material transfer
• Option
• Promotion
• Research
• Settlement
• Spin out
• Sub-license
• Supply
• Technology transfer
• Termination

Appendix 4 - Vaccines deals by therapy area

• Anaesthetics
• Cardiovascular
• Central Nervous System
• Dental
• Gastrointestinal
• Hematology
• Immunology
• Infectives
• Metabolic
• Musculoskeletal
• Oncology
• Ophthalmics
• Orphan disease
• Pediatrics
• Psychiatry
• Respiratory

Appendix 5 -Deal type definitions

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Vaccines partnering since 2010
• Figure 2: Active Vaccines dealmaking activity since 2010
• Figure 3: Vaccines partnering by deal type since 2010
• Figure 4: Vaccines partnering by disease type since 2010
• Figure 5: Vaccines deals with a headline value
• Figure 6: Vaccines deals with an upfront value
• Figure 7: Vaccines deals with a milestone value
• Figure 8: Vaccines deals with a royalty rate value
• Figure 9: Top Vaccines deals by value since 2010
• Figure 10: Most active Vaccines dealmakers since 2010
• Figure 11: Online partnering resources
• Figure 12: Forthcoming partnering events